» Articles » PMID: 19376612

Neuropathology of Nondemented Aging: Presumptive Evidence for Preclinical Alzheimer Disease

Abstract

Objective: To determine the frequency and possible cognitive effect of histological Alzheimer's disease (AD) in autopsied older nondemented individuals.

Design: Senile plaques (SPs) and neurofibrillary tangles (NFTs) were assessed quantitatively in 97 cases from 7 Alzheimer's Disease Centers (ADCs). Neuropathological diagnoses of AD (npAD) were also made with four sets of criteria. Adjusted linear mixed models tested differences between participants with and without npAD on the quantitative neuropathology measures and psychometric test scores prior to death. Spearman rank-order correlations between AD lesions and psychometric scores at last assessment were calculated for cases with pathology in particular regions.

Setting: Washington University Alzheimer's Disease Research Center.

Participants: Ninety-seven nondemented participants who were age 60 years or older at death (mean=84 years).

Results: About 40% of nondemented individuals met at least some level of criteria for npAD; when strict criteria were used, about 20% of cases had npAD. Substantial overlap of Braak neurofibrillary stages occurred between npAD and no-npAD cases. Although there was no measurable cognitive impairment prior to death for either the no-npAD or npAD groups, cognitive function in nondemented aging appears to be degraded by the presence of NFTs and SPs.

Conclusions: Neuropathological processes related to AD in persons without dementia appear to be associated with subtle cognitive dysfunction and may represent a preclinical stage of the illness. By age 80-85 years, many nondemented older adults have substantial AD pathology.

Citing Articles

APOEε4 alters ApoE and Fabp7 in frontal cortex white matter in prodromal Alzheimer's disease.

Moreno-Rodriguez M, Perez S, Malek-Ahmadi M, Mufson E J Neuroinflammation. 2025; 22(1):25.

PMID: 39885546 PMC: 11783964. DOI: 10.1186/s12974-025-03349-y.


Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis.

Almeida Z, Vaz D, Brito R Mol Neurobiol. 2024; 62(4):4391-4419.

PMID: 39446217 PMC: 11880078. DOI: 10.1007/s12035-024-04543-4.


Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease.

Salman Y, Gerard T, Huyghe L, Colmant L, Quenon L, Malotaux V Alzheimers Dement. 2024; 20(10):7205-7219.

PMID: 39254209 PMC: 11485073. DOI: 10.1002/alz.14235.


The Influence of Personality Traits on Driving Behaviors in Preclinical Alzheimer Disease.

Aschenbrenner A, Carr D, Benzinger T, Morris J, Babulal G Alzheimer Dis Assoc Disord. 2024; 38(3):241-248.

PMID: 39177169 PMC: 11524437. DOI: 10.1097/WAD.0000000000000632.


Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease.

Jury-Garfe N, Redding-Ochoa J, You Y, Martinez P, Karahan H, Chimal-Juarez E Acta Neuropathol. 2024; 148(1):15.

PMID: 39102080 PMC: 11300572. DOI: 10.1007/s00401-024-02775-1.


References
1.
Hebert L, Scherr P, Bienias J, Bennett D, Evans D . Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60(8):1119-22. DOI: 10.1001/archneur.60.8.1119. View

2.
Hulette C, Welsh-Bohmer K, Murray M, Saunders A, Mash D, McIntyre L . Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998; 57(12):1168-74. DOI: 10.1097/00005072-199812000-00009. View

3.
Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J . Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001; 58(9):1395-402. DOI: 10.1001/archneur.58.9.1395. View

4.
Castellani R, Lee H, Zhu X, Perry G, Smith M . Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008; 67(6):523-31. PMC: 2763411. DOI: 10.1097/NEN.0b013e318177eaf4. View

5.
Braak H, Braak E . Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997; 18(4):351-7. DOI: 10.1016/s0197-4580(97)00056-0. View